Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Rituximab and Cyclosporine for Idiopathic Membranous Nephropathy
NCT05782933Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Randomised, open-label trial of rituximab in idiopathic membranous nephropathy (IMN) (2 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: Remission of nephrotic syndrome at 12 months. Status: unknown.
02
Drugs
rituximab
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT05782933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05782933.